Loading
NASDAQHealthcareBiotechnology
Latest quote
$9.81
+$0.31 · +3.26%
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
Previous close
$9.81
+$0.31 · +3.26%
After-hours
$9.81
$0.00 · 0.00%
Oct 7, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
Day range
Current $9.81
52-week range
Current $9.81
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
88
Deep Value
Sentiment
72
Bullish
Risk
39
Moderate Risk
Momentum
71
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
Day range
Current $9.81
52-week range
Current $9.81
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 228.37M USD | 230.47M USD | 235.64M USD | 228.03M USD | 253.16M USD |
| Cost of goods sold | 58.16M USD | 64.4M USD | 62.68M USD | 55.09M USD | 63.7M USD |
| Gross profit | 170.21M USD | 166.06M USD | 172.96M USD | 172.94M USD | 189.45M USD |
| Research and development | 62.07M USD | 54.94M USD | 50.38M USD | 52.24M USD | 71.87M USD |
| Selling, general, and administrative | 71.21M USD | 80.16M USD | 89.31M USD | 89.98M USD | 116.29M USD |
| Operating expenses | 132.92M USD | 135.1M USD | 140.32M USD | 149.22M USD | 188.16M USD |
| Interest income | 4.08M USD | 4.72M USD | 2.61M USD | 813K USD | 160K USD |
| Interest expense | 6.62M USD | 12.45M USD | 13.33M USD | 11.59M USD | 12.81M USD |
| Depreciation and amortization | 10.94M USD | 11.52M USD | 11.52M USD | 9.84M USD | 11.31M USD |
| Operating income | 37.3M USD | 30.97M USD | 32.64M USD | 23.72M USD | 1.29M USD |
| Net income | 31.11M USD | 30.28M USD | 21.59M USD | 2K USD | −29.13M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Avantis U.S. Small Cap Value ETFAVUV22.77M0.07%30.86B USD0.25%$119.13-1.11%
Vanguard Morningstar Total Stock Market ETFVTI12.24M0.00%2.3T USD0.03%$381.03-0.40%
iShares Russell 2000 ETFIWM11.31M0.01%78.56B USD0.19%$277.7-1.29%
Vanguard Extended Market ETFVXF4.19M0.00%95.4B USD0.05%$233.49-1.56%
Dimensional - US Targeted Value ETFDFAT3.79M0.01%30.38B USD0.33%$67.08-1.29%
Dimensional - US Small Cap ETFDFAS3.72M0.01%34.14B USD0.31%$77.92-1.38%
Vanguard Russell 2000 ETFVTWO2.32M0.01%18B USD0.06%$112.21-1.26%
EA Bridgeway Omni Small-Cap Value ETFBSVO2.31M0.10%2.37B USD0.45%$28.29-0.90%Avantis U.S. Small Cap Value ETFAVUVVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFDimensional - US Targeted Value ETFDFATDimensional - US Small Cap ETFDFASVanguard Russell 2000 ETFVTWOEA Bridgeway Omni Small-Cap Value ETFBSVOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
